Global Microsclerotherapy Treatment Market Size, Share, and Growth Report 2030
The microsclerotherapy treatment market is predicted to increase at a 3.0% CAGR to USD 8,154.6 million by 2028, up from USD 6,829.4 million in 2021.
The market drivers, restrictions, and roadblocks to micro sclerotherapy treatment are investigated. This study takes into account recent advancements in the field of micro sclerotherapy therapy.
Microsclerotherapy Treatment Market: Overview
Microsclerotherapy is used to treat telangiectasia, a condition in which blood vessels near the skin’s surface or mucous membranes appear as red or pink lines. Telangiectasia is influenced by both genetic and environmental factors. Age, pregnancy, rosacea, prolonged sun exposure, and varicose veins are all risk factors for telangiectasia. There is no cure for this illness, however, it can be treated with micro sclerotherapy.
One of the primary factors driving the global micro sclerotherapy market is the increasing prevalence of spider and varicose veins. The comparatively painless therapy, low invasion, great efficacy, reduced post-operative problems, and simple analgesia required during treatment are all important factors moving the global market ahead. Spider veins are a kind of vein.
As a result, another aspect that could benefit the global industry is an increase in the number of aged people. Obesity, the prevalence of unhealthy lifestyles, and heredity may also have an impact on the growth of the worldwide micro sclerotherapy market during the forecast period.
The key factors that could impede worldwide market growth include rising treatment costs, a shortage of surgeon training, and other alternative methods.
Microsclerotherapy Treatment Market: Growth Drivers
The market is expanding because of an increase in female varicose veins.
The rising prevalence of spider and varicose veins is one of the primary factors driving the global market for micro sclerotherapy treatments. Varicose veins are expected to become more common in the coming years. According to the Occupational Health and Safety Research Center, 10% to 30% of persons globally have varicose veins in their lower limbs.
Women are twice as likely as men to have varicose veins. These disorders are substantial risk factors for spider veins in women because of the elevated expression of hormones such as progesterone and estrogen during pregnancy and subsequent pregnancies.
Microsclerotherapy Treatment Market: Segmentation
The global market for microsclerotherapy treatments has been divided into three subcategories: product type, end users, and region.
Sclerosants, sodium tetradecyl sulfate, polidocanol, chromated glycerin, hypertonic glucose, needles, and other products are included in the global microsclerotherapy treatment market. The sclerosants category will dominate the global market in 2021. The market for new sclerosants for spider vein therapy, such as polidocanol, sodium tetradecyl sulfate, and hypertonic saline, is expanding as a result of major producers’ marketing and development activities.
Microsclerotherapy Treatment Market: Competitive Landscape
Some of the main competitors dominating the global micro sclerotherapy treatment market include – Merz Pharma GmbH Co. KGaA, Surgimedix Inc, Troikaa, QOL Medical LLC, McKesson Corporation, Kreussler Inc, Provensis, ltd, Omega Pharmaceuticals, STD Pharmaceuticals Product Ltd, Medtronic Plc, Endo-Flex, Boston Scientific Corporation, and Teleflex Incorporated.
Global Microsclerotherapy Treatment Market is segmented as follows:
By Product Type
Sodium Tetradecyl Sulphate
By End Users
Aesthetic Treatment Clinics
Rest of Europe
Rest of Asia Pacific
Rest of Latin America
Middle East Africa
Rest of Middle East Africa
Zion Market Research
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL-FREE +1 (855) 465-4651
Email: [email protected]